In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Mesoblast pays $50mm up front for Osiris’ stem cell assets

Executive Summary

Mesoblast International SARL, a subsidiary of Australian biotech Mesoblast Ltd., acquired the culture-expanded mesenchymal stem cell (ceMSC) business of Osiris Therapeutics Inc. (tissue repair products and adult stem cell candidates) for $50mm up front, of which $35mm will be paid in cash ($20mm upon deal closing and $15mm in six months) and $15mm in Mesoblast stock (approximately 2.8mm shares based on Mesoblast’s 10-day average). Mesoblast takes ownership of 110 globally issued patents--including 48 in the US, 21 in Europe, 9 in Japan, and 32 in the rest of the world, encompassing composition-of-matter, uses, and methods claims with protection to 2025--plus patent applications, and clinical data from more than 1,500 patients.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Earnout
    • Intra-Biotech Deal
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies